VACCINI | AD26.COV2.S JOHNSON & JOHNSON
- MMWR, 27 aprile 2021 | “Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients”
- New England Journal of Medicine, 21 aprile 2021 | “Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19”
- AIFA, 12 marzo 2021 | “AIFA approva il vaccino Janssen”
- AIFA, 11 marzo 2021 | “EMA raccomanda l’autorizzazione nell’UE di COVID-19 Vaccine Janssen”
- MMWR, 2 marzo 2021 | “The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021”
- Nature, 29 gennaio 2021 | J&J’s one-shot COVID vaccine offers hope for faster protection-
- New England Journal of Medicine , 13 gennaio 2021 | ” Interim Results of a Phase 1–2a Trial of Ad26.COV2.SCovid-19 Vaccine”